The UK’s Treasury will ask the leaders of 19 banks and fintechs, including NatWest Group Plc, Lloyds Banking Group Plc, HSBC Holdings Plc and Barclays, to explain how they’ll ensure that customers aren’t “de-banked” for exercising free speech following a dust-up with Nigel Farage.
Elon Musk has changed Twitter’s logo, replacing its signature blue bird with a stylized X as part of the billionaire’s vision of transforming the 17-year-old service into an everything app.
Shares of Country Garden Holdings Co. are expected to drop 35% as liquidity concerns surrounding China’s private builders are unlikely to ease anytime soon, according to JPMorgan Chase & Co.
Busy For You, a Chinese snack shop chain, is considering an initial public offering that could raise $100 million to $200 million, according to people familiar with the matter.
The Sri Lankan rupee has turned into Asia’s worst-performing currency from being the best in the first half of the year, and is poised to extend losses amid headwinds from interest-rate cuts and loosening of import controls.
(Bloomberg) — Home prices are again on the rise after a brief dip last year, complicating the Federal Reserve’s effort to contain inflation and raising questions about how much further policymakers will have to hike interest rates.
The euro-area private-sector economy contracted more than anticipated in July, with order inflows and output expectations pointing to the downturn deepening in the coming months, according to S&P Global.
A late swing toward Prime Minister Pedro Sanchez’s Socialists denied his right-wing opponents a majority in parliament but leaves Spain facing months of instability without a fully functioning government.
It’s shaping up to be a pivotal week for global stocks, as companies with a combined $27 trillion market value gear up to report quarterly earnings. As Netflix Inc. and Tesla Inc. showed last week, the pressure is on — to deliver or face a sharp selloff.
Roche Holding AG will work together with Alnylam Pharmaceuticals Inc. on a potential treatment for high blood pressure in a deal worth as much as $2.8 billion, expanding the Swiss company’s footprint beyond the cancer therapies that long anchored its business.
